| socazolimab (STI-A1014) / Sorrento |
NCT03676985: A Clinical Study of PD-L1 Antibody ZKAB001(Drug Code) in Limited Stage of High-grade Osteosarcoma |
|
|
| Recruiting | 1/2 | 15 | RoW | ZKAB001 5mg/kg, PD-L1 monoclonal antibody, ZKAB001 10mg/kg, ZKAB001 15mg/kg | Lee's Pharmaceutical Limited | Osteosarcoma | 02/20 | 06/23 | | |
NCT03676946: A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Locally Advanced and Metastatic Urothelial Carcinoma |
|
|
| Recruiting | 1/2 | 15 | RoW | ZKAB001 5mg/kg, PD-L1 monoclonal antibody, ZKAB001 10mg/kg, ZKAB001 15mg/kg | Lee's Pharmaceutical Limited | Urothelial Carcinoma | 02/20 | 06/23 | | |
NCT04460066: A Study of Anti-PD-L1 Antibody in Neoadjuvant Chemotherapy of Esophageal Squamous Cell Carcinoma. |
|
|
| Active, not recruiting | 1/2 | 70 | RoW | anti-PD-L1 antibody, ZKAB001, Socazolimab Injection, albumin bound paclitaxel, ABRAXANE, cisplatin, placebo, radical resection of esophageal carcinoma | Lee's Pharmaceutical Limited | Esophageal Cancer | 12/21 | 07/23 | | |
NCT04849260: Phase Ib/II Clinical Study of Pexa-Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Combined With Recombinant Whole Human Anti-PD-L1 Monoclonal Antibody (ZKAB001) in Metastatic Melanoma |
|
|
| Recruiting | 1/2 | 54 | RoW | Pexa-Vec combined with ZKAB001, ZKAB001 monotherapy | Lee's Pharmaceutical Limited | Local Progression or Metastatic Melanoma With Failed First-line Treatment | 05/22 | 05/23 | | |
